Unity Biotechnology Company
Unity Biotechnology finds solutions against age-related diseases, such as vision loss and cognitive decline, cause considerable economic, personal, and societal burdens for individuals, their families, and broader communities. By targeting age-related diseases, we believe that UNITY can treat these diseases, as well as contain healthcare costs and lessen the emotional and societal burden that comes with an aging population.
Investors
Connections from
Founded Date:
2009
Investor Type:
IPO
Estimated Revenue:
$10M to $50M
Total Funding:
210.6M
Investors Number:
23
Employee Number:
51-100
Number Of Exists:
51-100
Last Funding Type:
Series C
Industry:
Drug Development, Gene therapy
Technology:
Geroscience
Headquarters:
Brisbane, California, United States
Funding Status:
Series C
Last Funding Date:
Mar 19, 2018